New research shows how early-life changes in gut bacteria can increase the risk of lifelong allergic diseases, offering insights into potential future treatments. Read more
Fasenra (Benralizumab) gains approval in China for treating severe eosinophilic asthma, offering new hope to millions of patients with limited treatment options. Learn more about this significant advancement Read more
Explore how a recent study used machine learning to localise and characterise mast cells in the pathology of EoE. Read more
Learn more about our paediatric care advocacy, networking and learn about the latest research we bring from the ESPGHAN Annual Meeting Read more
New study reveals that IL-10-producing regulatory B cells (Breg) could be key in treating atopic dermatitis by reducing inflammation and immune cell infiltration Read more
Pollen season can lower the response rate to the six-food elimination diet (SFED) in patients with Eosinophilic Oesophagitis (EoE), study shows. Read more
The study shows a high prevalence of GI disorders in hEDS/JHS patients, including constipation, dysphagia, and Eosinophilic Diseases. Read more
Messina Phase 3 trial results show benralizumab reduces eosinophil counts in EoE patients, with no notable improvement in dysphagia symptoms. Read more
Leading researcher Sarah Killcoyne shares the inspiration and aims of the trial on studying biomarkers in Eosinophilic Oesophagitis using an EndoSign® device. Read more
Learn more about EOS Network's participation at the London Marathon 2024, raising awareness for people with Eosinophil-Associated diseases. Read more
Explore a study that aims to understand why some people on eosinophil-directed treatments continue to have Eosinophilic Asthma flare-ups. Read more
Discover how Fasenra outperforms Nucala in treating Granulomatosis with Polyangiitis (EGPA), offering hope for reduced steroid use and improved remission. Read more
Discover how Total Wall Thickness measurement is transforming the diagnosis and management of Paediatric Eosinophilic Oesophagitis (EoE), offering a more direct insight into treatment efficacy and disease progression. Read more
FDA approves Takeda's EOHILIA® for treating Eosinophilic Oesophagitis (EoE). Learn more about the medication's mechanism of action. Read more
Discover key findings from Molly Shook's EoE study at Cincinnati Children’s Hospital’s Center for Autoimmune Genomics and Etiology (CAGE): novel genetic insights and future research directions. Read more
FDA has approved Dupixent (dupilumab) for children aged one to eleven, an important step for EoE management in young children and families. Read more
Discover how the EOS Network collaborates with Cyted to explore the capsule sponge test using EndoSign®, a promising alternative to endoscopic biopsies for EoE management. This study aims to improve patient experience and advance EoE treatment monitoring. Read more
New research reveals that the use of antibiotics and acid suppressants by mothers and infants may increase the risk of developing Eosinophilic Oesophagitis. Read more
This study sheds light on non-invasive blood biomarkers to potentially diagnose and manage Eosinophilic Oesophagitis. Read more
A study shows that patients with eosinophilic oesophagitis (EoE) and asthma seek hospital care earlier than those with only one condition. Read more
EOS Network attended the 75th BSACI Conference to connect with healthcare professionals and advocate for EoE awareness. Read more
Learn more about Dupixent and what impact its approval could have on treating EoE in younger children. Read more
Learn more about differences existing in care for children with eosinophilic oesophagitis, depending on race, urbanisation, and socioeconomic status. Read more
FDA to review Takeda's resubmission of Budesonide oral suspension - NDA of TAK-721, offering new hope for Eosinophilic Oesophagitis (EoE) patients. What does this mean for the eosinophilic community? Read more